Nuclear factor-kappaB (
NF-kappaB) plays a central role in
myocardial ischemia-reperfusion (MI/R) injury. The inhibitory
protein IkappaBalpha prevents its activation. We investigated the effects of adeno-associated viral vector-mediated
IkappaBalpha gene transfer in MI/R injury. Male C57BL/6 mice were randomized to receive a recombinant adeno-associated virus (rAAV) encoding the gene for the
NF-kappaB inhibitory
protein IkappaBalpha (rAAV-
IkappaBalpha) or the
beta-galactosidase gene (a control and inert gene; rAAV-LacZ), both at a dose of 10(11) copies. Four weeks later anesthetized animals were subjected to total occlusion (45 minutes) of the left main coronary artery followed by 5 hours of reperfusion. MI/R produced a wide
infarct size (IF/area-at-risk = 56 +/- 8%; IF/left ventricle = 44 +/- 5%) and tissue neutrophil infiltration, studied by means of
elastase activity (area-at-risk = 2.5 +/- 0.4 micro g/gm tissue;
infarct area = 2.9 +/- 0.6 micro g/gm tissue). Furthermore MI/R caused peak message for
intercellular adhesion molecule-1 (ICAM-1) in the area-at-risk at 3 hours of reperfusion (1.2 +/- 0.4 relative amount of cardiac ICAM-1
mRNA).
NF-kappaB activation was evident at 0.5 hours of reperfusion and reached its maximum increase at 2 hours of reperfusion. rAAV-
IkappaBalpha injection reduced
infarct size (IF/area-at-risk = 19 +/- 3%; IF/left ventricle = 10 +/- 2%; p < 0.001), blocked
NF-kappaB activation, diminished cardiac
ICAM-1 expression (0.4 +/- 0.02 relative amount of cardiac ICAM-1
mRNA; p < 0.001), and blunted leukocyte accumulation (area-at-risk = 0.6 +/- 0.05 micro g/gm tissue;
infarct area = 0.4 +/- 0.02 micro g/gm tissue; p < 0.001). Our data indicate that rAAV-
IkappaBalpha may be useful for MI/R gene
therapy.